DrugPatentWatch Database Preview
Eyevance Company Profile
What is the competitive landscape for EYEVANCE, and when can generic versions of EYEVANCE drugs launch?
EYEVANCE has five approved drugs.
There are four US patents protecting EYEVANCE drugs.
There are fifteen patent family members on EYEVANCE drugs in five countries and two supplementary protection certificates in two countries.
Summary for Eyevance
| International Patents: | 15 |
| US Patents: | 4 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Eyevance
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eyevance | ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694-001 | May 30, 2017 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Eyevance | ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694-001 | May 30, 2017 | RX | Yes | Yes | 8,829,005*PED | Start Trial | Y | Start Trial | |||
| Eyevance | ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694-001 | May 30, 2017 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Eyevance | ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694-001 | May 30, 2017 | RX | Yes | Yes | 9,750,684 | Start Trial | Y | Start Trial | |||
| Eyevance | VEXOL | rimexolone | SUSPENSION/DROPS;OPHTHALMIC | 020474-001 | Dec 30, 1994 | DISCN | No | No | Start Trial | Start Trial | |||||
| Eyevance | TOBRASONE | fluorometholone acetate; tobramycin | SUSPENSION/DROPS;OPHTHALMIC | 050628-001 | Jul 21, 1989 | DISCN | No | No | Start Trial | Start Trial | |||||
| Eyevance | FLAREX | fluorometholone acetate | SUSPENSION/DROPS;OPHTHALMIC | 019079-001 | Feb 11, 1986 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Eyevance
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eyevance | TOBRASONE | fluorometholone acetate; tobramycin | SUSPENSION/DROPS;OPHTHALMIC | 050628-001 | Jul 21, 1989 | 5,149,693 | Start Trial |
| Eyevance | VEXOL | rimexolone | SUSPENSION/DROPS;OPHTHALMIC | 020474-001 | Dec 30, 1994 | 4,686,214 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Eyevance Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2547340 | Start Trial |
| European Patent Office | 2408453 | Start Trial |
| Japan | 6033677 | Start Trial |
| Japan | 2016190878 | Start Trial |
| Japan | 2016190879 | Start Trial |
| Japan | 6144393 | Start Trial |
| Mexico | 2011009802 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Eyevance Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0663828 | C300085 | Netherlands | Start Trial | PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103 |
| 0058146 | 2001C/045 | Belgium | Start Trial | PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
